Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Accumulated Expenses data on record, last reported at $16.0 million in Q3 2025.

  • For Q3 2025, Accumulated Expenses rose 106.79% year-over-year to $16.0 million; the TTM value through Sep 2025 reached $16.0 million, up 106.79%, while the annual FY2024 figure was $13.1 million, 101.01% up from the prior year.
  • Accumulated Expenses reached $16.0 million in Q3 2025 per DNTH's latest filing, up from $14.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $16.0 million in Q3 2025 and bottomed at $1.6 million in Q1 2023.
  • Average Accumulated Expenses over 4 years is $7.9 million, with a median of $6.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: tumbled 75.55% in 2023, then surged 273.13% in 2024.
  • A 4-year view of Accumulated Expenses shows it stood at $6.6 million in 2022, then fell by 1.57% to $6.5 million in 2023, then soared by 101.01% to $13.1 million in 2024, then grew by 22.22% to $16.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $16.0 million in Q3 2025, $14.0 million in Q2 2025, and $8.0 million in Q1 2025.